Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GLPG3121 Modified Release in Healthy Men
NCT04856358Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Apr 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GLPG3121 in Inflammatory Disorders (6 arms), sponsored by Galapagos NV. Primary endpoint: Treatment-Emergent Adverse Events. Started Apr 2021; status: completed.
02
Drugs
GLPG3121
03
Conditions
Inflammatory Disorders
Beyond the preview
Go deeper on NCT04856358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04856358.